Peripheral blood gene expression profile of atherosclerotic coronary artery disease in patients of different ethnicity in Malaysia

Journal of Cardiology

Volumn 60, Issue 3, 2012, Pages 192-203

  Abdullah, Mohd Hafiz Ngoo ^a   Othman, Zulhabri ^b   Noor, Hamdan Mohd ^a   Arshad, Siti Suri ^c   Yusof, Ahmad Khairuddin Mohd ^d   Jamal, Rahman ^b   Rahman, Abdul Rashid Abdul ^a  

^a CYBERJAYA UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (Malaysia)

^b UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^c UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^d NATIONAL HEART INSTITUTE   (Malaysia)

Author keywords

Coronary artery disease; Gene expression; IL1B; Malaysia; MMP9; SOD2

Indexed keywords

ALPHA2 INTEGRIN; ALPHA2B INTEGRIN; BETA3 INTEGRIN; BIOLOGICAL MARKER; CYSTATHIONINE BETA SYNTHASE; GELATINASE B; GHRELIN; HAPTOGLOBIN; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 18 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 18 RECEPTOR ALPHA; INTERLEUKIN 1BETA; LYMPHOTOXIN; MANGANESE SUPEROXIDE DISMUTASE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 GROUP VII; UNCLASSIFIED DRUG; UROTENSIN II;

ADULT; ANGIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DOWN REGULATION; ETHNICITY; GENE EXPRESSION PROFILING; GENETIC MARKER; HUMAN; MALAYSIA; MALE; UPREGULATION;

BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; DOWN-REGULATION; ETHNIC GROUPS; GENE EXPRESSION; HUMANS; MALAYSIA; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; SOFTWARE; UP-REGULATION;

EID: 84866173843     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.05.009     Document Type: Article

References (36)

1. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
2. Arnett D.K., Baird A.E., Barkley R.A., Basson C.T., Boerwinkle E., Ganesh S.K., Herrington D.M., Hong Y., Jaquish C., McDermott D.A., O'Donnell C.J. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2007, 115:2878-2901.
3. Bijnens A.P., Lutgens E., Ayoubi T., Kuiper J., Horrevoets A.J., Daemen M.J. Genome-wide expression studies of atherosclerosis. Critical issues in methodology, analysis, interpretation of transcriptomics data. Arterioscler Thromb Vasc Biol 2006, 26:1226-1235.
4. Debey S., Zander T., Brors B., Popov A., Eils R., Schultze J.L. A highly standardized, robust, and cost-effective method for genome-wide transcriptome analysis of peripheral blood applicable to large-scale clinical trials. Genomics 2006, 87:653-664.
5. Fan H., Hegde P.S. The transcriptome in blood: challenges and solutions for robust expression profiling. Curr Mol Med 2005, 5:3-10.
6. Aziz H., Zaas A., Ginsburg G.S. Peripheral blood gene expression profiling for cardiovascular disease assessment. Genomic Med 2007, 1:105-112.
7. Safiah M.Y. Coronary heart disease mortality in peninsular Malaysia. Med J Malaysia 1996, 51:392-395.
8. Heng D.M., Lee J., Chew S.K., Tan B.Y., Hughes K., Chia K.S. Incidence of ischaemic heart disease and stroke in Chinese, Malays and Indians in Singapore: Singapore Cardiovascular Cohort Study. Ann Acad Med Singapore 2000, 29:231-236.
9. Barnes M., Freudenberg J., Thompson S., Aronow B., Pavlidis P. Experimental comparison and cross-validation of the Affymetrix and Illumina gene expression analysis platforms. Nucleic Acids Res 2005, 33:5914-5923.
10. Wright C., Bergstrom D., Dai H.Y., Marton M., Morris M., Tokiwa G., Wang Y.Q., Fare T. Characterization of globin RNA interference in gene expression profiling of whole-blood samples. Clin Chem 2008, 54:396-405.
11. Orr M., Liu P. Sample size estimation while controlling false discovery rate for microarray experiments using the ssize.fdr package. R J 2009, 1:47-53.
12. Liu P., Hwang J.T.G. Quick calculation for sample size while controlling false discovery rate with application to microarray analysis. Bioinformatics 2007, 23:739-746.
13. Dennis G., Sherman B.T., Hosack D.A., Yang J., Gao W., Lane H.C., Lempicki R.A., Davi D. Database for annotation, visualization, and integrated discovery. Genome Biol 2003, 4:P3.
14. Huang D.W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID. Bioinform Resour - Nat Protoc 2009, 4:44-57.
15. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B (Methodological) 1995, 57(1):289-300.
16. Kai H., Ikeda H., Yasukawa H., Kai M., Seki Y., Kuwahara F., Ueno T., Sugi K., Imaizumi T. Peripheral blood levels of matrix metalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998, 32:368-372.
17. Blankenberg S., Rupprecht H.J., Poirier O., Bickel C., Smieja M., Hafner G., Meyer J., Cambien F., Tiret L. AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003, 107:1579-1585.
18. Tayebjee M.H., Lip G.Y., Tan K.T., Patel J.V., Hughes E.A., MacFadyen R.J. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol 2005, 96:339-345.
19. Tang Q.D., Wu P.S., Hou Y.Q., Huang Z., Zhou Z.J., Guo Z.G., Xiu J.C., Wang Y.G. Plasma matrix metalloproteinases-2 and -9 levels are elevated in patients with acute coronary syndrome and coronary chronic total occlusion. J Southern Med Univ (Nan Fang Yi Ke Da Xue Xue Bao) 2009, 29:1004-1007.
20. Jefferis B.J., Whincup P., Welsh P., Wannamethee G., Rumley A., Lennon L., Thomson A., Lawlor D., Carson C., Ebrahim S., Lowe G. Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis 2010, 208:557-563.
21. Galis Z.S., Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002, 90:251-262.
22. Fukuda D., Shimada K., Tanaka A., Kusuyama T., Yamashita H., Ehara S., Nakamura Y., Kawarabayashi T., Iida H., Yoshiyama M., Yoshikawa J. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol 2006, 97:175-180.
23. Wang J., Warzecha D., Wilcken D., Wang X.L. Polymorphism in the gelatinase B gene and the severity of coronary arterial stenosis. Clin Sci (Lond) 2001, 101:87-92.
24. Kim J.S., Park H.Y., Kwon J.H., Im E.K., Choi D., Jang Y., Cho S.Y. The roles of stromelysin-1 and the gelatinase B gene polymorphism in stable angina. Yonsei Med J 2002, 43:473-481.
25. Haberbosch W., Gardemann A. Gelatinase B (C-1652 T) polymorphism in relation to ischaemic heart disease. Scand J Clin Lab Invest 2005, 65:513-522.
26. Wæhre T., Damås J.K., Gullestad L., Holm A.M., Pedersen T.R., Arnesen K.E., Torsvik H., Frøland S.S., Semb A.G., Aukrust P. Hydroxymethylglutaryl coenzyme A reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol 2003, 41:1460-1467.
27. Wispé J.R., Clark J.C., Burhans M.S., Kropp K.E., Korfhagen T.R., Whitsett J.A. Synthesis and processing of the precursor for human mangano-superoxide dismutase. Biochim Biophys Acta 1989, 994:30-36.
28. Victor V.M., Rocha M., Solá E., Bañuls C., Garcia-Malpartida K., Hernández-Mijares A. Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharm Des 2009, 15:2988-3002.
29. Ballinger S.W., Patterson C., Knight-Lozano C.A., Burow D.L., Conklin C.A., Hu Z., Reuf J., Horaist C., Lebovitz R., Hunter G.C., McIntyre K., Runge M.S. Mitochondrial integrity and function in atherogenesis. Circulation 2002, 106:544-549.
30. Chrissobolis S., Didion S.P., Kinzenbaw D.A., Schrader L.I., Dayal S., Lentz S.R., Faraci F.M. Glutathione peroxidase-1 plays a major role in protecting against angiotensin II-induced vascular dysfunction. Hypertension 2008, 51:872-877.
31. Chiang H.S., Maric M. Lysosomal thiol reductase negatively regulates autophagy by altering glutathione synthesis and oxidation. Free Radic Biol Med 2011, 51:688-699.
32. Libby P., Theroux P. Pathophysiology of coronary artery disease. Circulation 2005, 111:3481-3488.
33. Archacki S.R., Angheloiu G., Tian X.L., Tan F.L., DiPaola N., Shen G.Q., Moravec C., Ellis S., Topol E.J., Wang Q. Identification of new genes differentially expressed in coronary artery disease by expression profiling. Physiol Genomics 2003, 15:65-74.
34. Feezor R.J., Baker H.V., Mindrinos M., Hayden D., Tannahill C.L., Brownstein B.H., Fay A., MacMillan S., Laramie J., Xiao W., Moldawer L.L., Cobb J.P., Laudanski K., Miller-Graziano C.L., Maier R.V., et al. Whole blood and leukocyte RNA isolation for gene expression analyses. Physiol Genomics 2004, 19:247-254.
35. Sluimer J.C., Kisters N., Cleutjens K.B., Volger O.L., Horrevoets A.J., van den Akker L.H., Bijnens A.P.J., Daemen M.J. Dead or alive: gene expression profiles of advanced atherosclerotic plaques from autopsy and surgery. Physiol Genomics 2007, 30:335-341.
36. Taurino C., Miller W.H., McBride M.W., McClure J.D., Khanin R., Moreno M.U., Dymott J.A., Delles C., Dominiczak A.F. Gene expression profiling in whole blood of patients with coronary artery disease. Clin Sci (Lond) 2010, 119:335-343.